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gNTRODUCTION
Professor Eliane Gluckman, MD, was this year’s
onored E. Donnall Thomas lecturer at the Tandem
one Marrow Transplant (BMT) Meetings, held on
ebruary 18, 2006, in Honolulu, Hawaii. Dr Gluckman
as born and trained in Paris, France, and is currently
ead of Faculty in the Department of Hematology at
he Hospital St Louis, Paris. After her residency, she was
fellow of Professor Thomas in Seattle, Washington.
rom that point on, Dr Gluckman has always been very
ctive in the ﬁeld of allogeneic stem cell transplantation,
ith a focus on advancing methods for the prevention
nd treatment of graft-versus-host disease (GVHD) and
he development of programs to facilitate alternative
onor transplants for those patients without an HLA-
dentical sibling. In 1988, she established a phenomenal
nd productive initial collaboration with Dr Hal Brox-
eyer and A. D. Auerbach to introduce the concept of
mbilical cord blood transplantation (CBT) to the ﬁeld.
ince then, Dr Gluckman has been at the forefront of
BT research that has seen the approach become very
uch a standard of practice for children who are not
ortunate enough to have an HLA-identical sibling do-
or. The practical use of unrelated donor CBT has also
een gaining recognition for use in adults and may be
onsidered a better option for patients than transplanta-
ion of matched unrelated blood or bone marrow cells.
he following text is a modiﬁed transcribed version of
he presentation made by Dr. Gluckman.
DDRESS
I will discuss today the current results and future
or CBT. We know that, in cord blood, there is a high q
08umber of hematopoietic stem cells that can be trans-
lanted to treat a large variety of hematopoietic dis-
rders. More recently, and this is a new exciting ﬁnd-
ng, we found that cord blood also contains
onhematopoietic stem cells that might be used in the
uture for tissue and organ replacements.
The story of the clinical application of cord blood
egan in 1988. I’m very grateful that Dr Hal Brox-
eyer, in New York and now in Indianapolis, called
e in Paris and asked me if I wanted to perform a
BT for a patient with Fanconi anemia. We had
lready been collaborating with Dr Arleen Auerbach
t Rockefeller University on the diagnosis and treat-
ent of Fanconi anemia. Our group was the ﬁrst to
escribe the successful use of a nonmyeloablative con-
itioning in Fanconi anemia, demonstrating that the
NA repair defect in this disease made the patients
nable to tolerate high-dose cyclophosphamide. For
his reason, I was asked to perform this ﬁrst CBT to
ptimize the chance of success.
This transplant was really straightforward. The
nly difference between this transplant and a normal
one marrow transplant (BMT) was that, instead of
sing bone marrow cells from the HLA-matched sib-
ing donor, we used the sibling cord blood that had
een cryopreserved at birth. We knew before birth
hat this donor was HLA-identical and not affected by
he disease. The patient had a very uneventful engraft-
ent; he is now followed by Dr Joanne Kurtzberg at
uke University and is still doing well. It was the ﬁrst
emonstration that cord blood could generate a long-
erm hematopoietic and immunologic reconstitution.
After the publication of this case in the New En-
land Journal of Medicine, several questions were fre-
uently asked. First, what was the general applicability
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Cord Blood Transplantation 809f CBT? Was it only for a rare congenital disease with
n HLA-identical sibling, or would it be applicable for
ll BMT indications? Nowadays, we can say yes, CBT
as been used in a large variety of malignant and
onmalignant diseases. The second question was:
ould it engraft properly? The question was asked
ecause we know that in a single cord, there is one-
enth the number of cells as in a marrow collection.
e can say yes, it can engraft children and adults, but
ngraftment is delayed. Would HLA incompatible
rafts be feasible? The immunologic system is imma-
ure at birth, and we know that lymphoid cells from
ord blood are naive, immature, and have decreased
eactivity. We have shown that mismatched trans-
lants were possible and that there was a decreased
ncidence and severity of acute and chronic GVHD.
nother question that is not discussed anymore but
as important at that time was the possibility that
here would be maternal cells in cord blood that could
ngraft and give rise to severe acute GVHD. We
onducted a study of this issue and found that, indeed,
here were maternal cells in cord blood, but not in
ery high numbers. However, even if they were de-
ectable, we have not seen a single case of engraftment
f these cells, nor of GVHD related to this contami-
ation. So we think it is irrelevant. Finally, it was also
uestioned whether it was safe to collect cord blood at
irth. Would it deprive the infant of important cells?
his has been thoroughly studied, and we can say that
t is safe and that the amount of 100 mL of cord blood
ollected after birth is harmless to the child.
After the ﬁrst CBT was performed in 1988, the
ext step was the clinical observation that GVHD was
educed compared with HLA-matched BMT. The
rst paper we published with Center for International
one Marrow Transplant Research (CIBMTR)
howed that, in children receiving an HLA-identical
ibling transplants, either from bone marrow or from
ord blood, the outcomes were the same in terms of
urvival and engraftment, but the big difference was
hat the level of acute and chronic GVHD was re-
uced in the latter. This observation was also repro-
uced in unrelated HLA-mismatched CBT. Based on
hese ﬁndings, cord blood banks were established for
nrelated transplants, and the 4 major banks were in
ew York, Paris, Milan, and Düsseldorf. Since then,
here has been extensive cord blood banking activity,
nd now there are more than 200 000 U stored world-
ide.
In 1995, we established Eurocord whose aim was
o collect data on cord blood transplants worldwide.
ur group and others showed that the nucleated cell
ount was the most important factor for engraftment
nd survival and that there was some inﬂuence of
LA on engraftment. More recently, it has been
hown that CBT can be performed not only in chil-
ren but also in adults, the results of which are com- 7arable to unrelated BMT. New exciting results com-
ng from the Minnesota group showed that double
BT can give good results with a decrease of relapse
ates, and that it is possible to condition with a non-
yeloablative regimen.
To review CBT results, the Eurocord registry has
ollected data from 2310 CBTs performed from 1988
o October, 2005, provided by 318 transplantation
enters in 39 countries. Of these, 1500 blood cases
ame from European Blood and Marrow Transplant
EBMT) centers and 742 came from non-EBMT cen-
ers. Overall, the reports indicated that the number of
elated CBT performed annually has really not in-
reased over the years, although probably not all of
hem have been reported. In contrast, there was a
harp increase in the number of unrelated CBTs in
004 and 2005. The proportion of children has
hanged with time, with more adults transplanted re-
ently.
Concerning the 261 cases of related CBT, their
umber did not increase with time; all were children,
0% were transplanted for malignant diseases (Acute
ymphoblastic Leukemia (ALL) and Acute Myelo-
lastic Leukemia (AML)) and 40% for nonmalignant
iseases, mostly bone marrow failure syndromes, met-
bolic disease, and hemoglobinopathies. For these lat-
er recipients, there was 100% survival and 86%
vent-free survival. Due to these extremely good re-
ults, we are trying to promote—and we are doing that
xtensively in Paris—cord blood collection in siblings
f patients with sickle cell anemia, which is relatively
asy to do in families of African origin. For patients
ith bone marrow failure syndromes, including Fan-
oni anemia, constitutional aplastic anemia and idio-
athic aplastic anemia, CBT resulted in 63% survival
nd 51% event-free survival.
For unrelated CBT, we collected data from 1320
hildren and 693 adults, the majority with malignant
iseases (962), mostly acute and chronic leukemia,
ymphoma. and myeloma. In 270 cases of nonmalig-
ant diseases, we collected 113 cases of aplastic ane-
ia, 124 cases of severe combined immunodeﬁciency,
nd 89 cases of metabolic diseases. Survival for ALL
as 50% in ﬁrst complete remission (CR1), 45% in
econd complete remission (CR2), with no difference
etween CR1 and CR2, and 29% in more advanced
isease. For AML, survival was 70% in CRI, 55% in
R2, and 27% for more advanced disease. These
esults are quite interesting for totally mismatched
ransplants and quite comparable with the results of
atched unrelated bone marrow transplants. Survival
ollowing CBT for children with congenital disease
as 68%, metabolic disease 63%, and congenital bone
arrow failure syndrome 43%. For the latter group,
eparation into patients with Fanconi anemia, 49%,
nd congenital marrow failure syndrome is around
0% survival. For adult CBT before 1998, there was
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E. Gluckman810nly 20% survival. In CBT performed after 1988,
here was 30% survival, because both the quality of
he transplant and the selection of the patients im-
roved.
Within the Netcord organization, we were able to
et up standards with the FACT/Netcord accredita-
ion to ensure good quality units and to be able to
xchange units all around the world. Of the more than
00 000 units that have been collected, 3942 have
een used for transplant, 2300 have been used for
hildren, and 1500 for adults.
There has been discussion about the autologous
ord blood banking and the relation between public
nd private banks. Most of these banks are located in
he United States, some are in Europe, but some
ountries do not authorize it. In Asia, the proportion
f private banks is high. There have been a lot of
thical discussions on this topic because the rationale
or autologous cord banking is not clearly established.
he approach has been advertised as biological insur-
nce for the future of the newborn, in that nonhema-
opoietic stem cells, that are present in cord blood,
ight later be useful. Although there is extensive
esearch on nonhematopoietic stem cells in cord
lood, it’s not yet ready for clinical use, so there is a lot
f controversy about selling a product for which the
linical use has not yet been proven.
During this period, most of our work had been to
ompare the result of unrelated mismatched CBT
ith the results of unrelated matched BMT. In a study
hat we did in 2001, in children with acute leukemia,
e compared outcomes for 3 groups of patients—
hose who had received a T-replete unrelated BMT, a
-depleted unrelated BMT, or an unrelated CBT.
e found that there was a delay of engraftment in the
BT recipients, although it was the same as in T-
eplete BMT. There was increased transplant-related
ortality and this was due to the delay of engraftment.
owever, the number of earlier relapse in the T-
epleted group was higher, and for long-term out-
omes, the proportion of chronic GVHD was the
ame between the CBT and T-depleted BMT groups,
ompared with the higher proportion in the T-replete
MT group. Overall, there was no difference between
he unrelated BMT and CBT in terms of survival and
vent-free survival.
In another study by Juliet Barker, published in
lood in 2001, and 2 other studies, published in Bone
arrow Transplantation in 2004, the same results were
ound: delay of engraftment, diminishment of acute
nd chronic GVHD, same or higher transplant-re-
ated morbidity, same relapse rate, and same survival.
he implication for unrelated donor selection in chil-
ren is that the choice depends on the clinical situa-
ion. Cord blood is quickly available, especially in
atients who need an urgent transplant or do not have
n HLA-identical donor. In a combined study by eIBMTR and Cord Blood New York (CBNY) on
BT for children, which was presented at the recent
merican Society of Hematology (ASH) meeting, bet-
er results with matched CBT compared with matched
MT were observed.
The same comparison in adults with acute leuke-
ia receiving either an unrelated CBT or a BMT was
ublished in the New England Journal of Medicine in
004. We showed that neutrophils and platelets en-
raftment was delayed. Acute GVHD was reduced,
nd chronic GVHD was the same. In regard to long-
erm survival, transplant-related mortality was the
ame, relapse was the same, and leukemia-free survival
as the same in both groups. Our conclusion was that
atched unrelated BMT had results that were similar
o HLA-mismatched CBT.
In the same issue of the New England Journal of
edicine, Mary Laughlin et al compared BMT and
BT in adults with leukemia. The results were not
xactly similar, but comparable to our study. The best
esults were obtained with HLA-identical unrelated
MT and CBT with 1 antigen mismatch and were
omparable to BMT with 1 antigen mismatch. At the
ame time, the Japanese group published in Blood in
004 a single-institution comparative analysis of un-
elated matched BMT and CBT for patients with
ematological malignancies. The results were quite
ifferent, with CBT leading to 70% survival com-
ared with 40% after BMT. The cause of the differ-
nce in survival seemed due to higher levels of GVHD
nd infection in the BMT group.
To summarize, we can say that, in adults, mis-
atched CBT compared with HLA-matched unre-
ated BMT gives delayed engraftment, decreased or
ame acute GVH, decreased or same chronic GVHD,
ncreased or same transplant-related mortality, and
imilar degree of survival. The conclusion is that CBT
s an alternative source of stem cells in adults with
igh-risk hematological disorders, without a matched
one marrow donor.
We conducted a new study in which we looked at
he impact of HLA compatibility and cell dose on
utcomes of unrelated CBT for patients with malig-
ant and nonmalignant disorders. We reviewed all
atients transplanted from 1994 to 2005 and analyzed
eparately malignant (929 patients) and nonmalignant
268 patients) disorders. In patients with malignant
iseases, the median follow-up time was 28 months,
he median age was 11 years (range, 2 months to 56
ears), and the disease characteristics were: AML
0%; ALL 47%; chronic leukemia 9%; Myelodysplas-
ic Syndrome (MDS) 10%; other 4%. The status was
3% early; 46% intermediate; and 31% advanced dis-
ase. With HLA compatibility determined by antigen
yping for class I antigens and allelic typing for class II
ntigens, 9% were HLA identical, 42% had 1 differ-
nce, 40% had 2 differences, and 9% had 3 or 4 HLA
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Cord Blood Transplantation 811ifferences. The median number of nucleated cells
NCs) at collection was 4.4  107/kg. The median
ose infused was 3.1  107 NCs/kg and the median
D34 cells infused was 1.4  105 NCs/kg.
First, we conﬁrmed the role of cell dose on en-
raftment. The minimum cell dose collected was less
han 3  107/kg, and the minimum dose of cells
nfused was 2  107 NCs/kg. HLA number of mis-
atches was also an important factor for engraftment
ith increased delay of engraftment according to the
umber of HLA mismatches (0-4 mismatches). The
uestion was whether this difference was related to the
umber of cells infused. For 0-1 mismatch, there was
difference, meaning that if there were more than 2
07/kg infused cells, there was a better engraftment.
or 2-4 HLA differences, the effect on engraftment
as abrogated by increasing cell dose. There was no
ifference according to either HLA class I or class II
ismatches. For blood platelet recovery, the effect of
ell dose was even more important, and there was also
o difference between class I and class II mismatches.
or II-IV acute GVHD, we did not ﬁnd any effect of
ell dose, nor any effect of the number of HLA mis-
atches. However, it seemed that class II mismatches
ave more GVHD. For chronic GVHD, we found a
orrelation of higher incidence with the fewer cells
ransplanted, and we found a signiﬁcant effect of HLA
ismatches. Cord blood cell dose inﬂuenced trans-
lant-related mortality. For HLA, the more matched,
he better the survival, but increasing the cell dose
brogated the effect of HLA mismatches. For exam-
le, in a group with 3-4 mismatches, the transplant-
elated mortality was 20% versus 40% with an in-
reased dose of cells for the same number of HLA
ismatches. It was worse to be transplanted with 2
LA class II mismatches rather than 2 class I mis-
atches. Relapse was higher with 0-1 HLA mismatch
ompared with 2-4 HLA mismatches. This explains
hy survival was not inﬂuenced by the number of
LA mismatches. The survival for early and interme-
iate stages of transplant was 38%, whereas it was
0% in advanced disease. Increasing cord blood cell
ose improved survival. There was no effect of HLA
n disease-free survival, although it was slightly better
ith 2 class II mismatches. This effect on the disease-
ree survival was due to the reduction of relapse rate
ccording to the number of HLA mismatches, result-
ng in the same survival. When looking at the effect of
he cell dose and the number of the HLA mismatches,
3-4 HLA antigen mismatched CBT with a high cell
ose gave better results than a 3-4 HLA antigen mis-
atched CBT with a low cell dose.
To summarize, increasing the number of HLA
ismatches delayed engraftment, increased trans-
lant-related mortality, chronic GVHD, decreased re-
apse, and resulted in the same overall and disease-free
urvival. Considering the interaction between HLA mnd the number of cells, the worst group was 3-4
ntigen HLA mismatches, with less than 2  107/kg
ononuclear cells infused, because it delayed engraft-
ent and increased transplant-related mortality. It
ad no effect on acute and chronic GVHD, and re-
apse was decreased by lowering the number of mis-
atches and increasing the number of cells. Overall
urvival was decreased with more HLA mismatches
nd fewer cells.
In conclusion, cell dose is the most important
actor for outcome—requiring a minimum of 3  107
Cs at collection, or 2  107 NCs/kg at infusion.
LA mismatches increase the risk of delays of en-
raftment and increase transplant mortality and
hronic GVHD, and decrease the risk of relapse. The
ype of HLA mismatch did not seem to have an effect,
ut matching for HLA class II seems better. Increas-
ng cell dose overcomes the effect of HLA mis-
atches.
For nonmalignant disorders, we analyzed 268 pa-
ients with a median follow-up time of 32 months;
edian age was 3 years (range, 22 days to 53 years);
0% of patients had aplastic anemia, 36% had severe
ombined immunodeﬁciency, and 24% a metabolic
isorder; 18% were HLA identical CBT, 43% had 1
LA mismatch, 35% had 2 HLA mismatches, and 4%
ad 3 and 4 antigen mismatches. Because most of the
atients were children, the number of cells infused was
igher than in malignant disease. It was 8.5  107
Cs/kg before freezing and 6.4  107 NCs/kg in-
used, and the median number of CD34cells was 2
06/kg. The median cell loss was 27%.
The cell requirement was higher, and fewer than
.9  107 NCs/kg collected gave a low rate of en-
raftment. For the infused cells, it was fewer than 3.5
107/kg compared with 2.0  107/kg for malignant
iseases. We observed that increasing the cell dose
nhanced engraftment and overcame effects of HLA
ismatches. Acute and chronic GVHD were inﬂu-
nced by the number of HLA mismatches. We found
he same result for transplant-related mortality, with
he best outcome for 0-1 HLA mismatch and a high
ell dose. The overall survival for the group of patients
ith primary immunodeﬁciency was 65%, metabolic
isease 50%, and bone marrow failure syndrome 35%.
ooking at survival according to the number of cells,
e found that for the high cell dose it was 60% and
ess than 40% in the low cell dose group. A cell dose
f less than 3.5  107 NCs/kg gave a very poor
urvival. Survival was affected by the number of HLA
ismatches and the cell dose; it was different from the
alignant diseases where HLA mismatches did not
nﬂuence survival, because there was no need for a
raft-versus-leukemia response.
In conclusion, requirements for cell dose and
LA mismatching are different in malignant and non-
alignant diseases. In nonmalignant diseases, mini-
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E. Gluckman812um cell dose is higher, 4  107/kg at collection and
.5  107/kg at infusion. In addition, more than a 2
LA-antigen mismatch CBT affects engraftment,
VHD, and survival, but can be partially abrogated
y increasing cell dose.
There are many new CBT protocols under inves-
igation, but I would like to focus on one of the more
xciting advances in the ﬁeld, and that is the double
ord transplant program pioneered by the Minnesota
roup. Because cell dose is very important to the
uccess of CBT, the idea was to increase the dose by
iving 2 separate HLA-mismatched CBT. This atti-
ude was really against the dogma because the risk of
iving 2 different transplants was that each transplant
ould reject the other, and if eventually it would take,
ome allogeneic reaction could impair the immune
econstitution capacity of this transplant. Surprisingly,
here was rejection of 1 donor’s stem cells, but the
ther 1 always survived, and this conﬂict facilitated
ngraftment by a still unknown mechanism.
Another possibility to improve engraftment was to
se cytokine factors and give ex vivo expanded cells.
here are currently several studies with this approach,
ut it is too early to know if it will work. Other options
re to give the cells directly into the bone to avoid loss
f the cells before homing or to add mesenchymal
ells to improve engraftment. An alternative new and
ery attractive approach, also pioneered by the Min-
esota group, is to use a nonmyeloablative condition-
ng regimen. Preliminary results indicate that this ap-
roach works, so we will have to follow that very
arefully.
An exciting area that may have an effect on CBT
s the prospect of regenerative medicine. To use stem
ells for cell therapy, cell repair, or “regenerative”
edicine, there are different sources, ie, embryonic,
ord blood, or adult stem cells, all of which have
peciﬁc advantages and disadvantages. Umbilical cord
s highly proliferative, can divide into almost all dif-
erent cell types, and can be autologous or allogeneic.
owever, it is only available once in a lifetime and its limited in quantity. The hope is that embryonic
roperties are retained in cord blood stem cells, mak-
ng these cells the ideal source for all possible clinical
pplications in the future. We can thus conclude that
ord blood is a unique biological resource for hema-
opoietic transplantation, regenerative medicine, and
cientiﬁc research, and, therefore, there is a need for
ncreasing the number of units stored.
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